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Abstract. Despite its importance, the death rate of ovarian 
cancer has remained unchanged over the past five decades, 
demanding an improvement in prevention and treatment of 
this malignancy. With no known carcinogens, targeted preven-
tion is currently unavailable, and efforts in early detection of 
this malignancy by screening biomarkers have failed. The 
inhibition of angiogenesis, also known as angioprevention, 
is a promising strategy to limit the growth of solid tumors, 
including ovarian cancers. Nobiletin, a polymethoxy flavonoid 
compound isolated from the tiansheng plant, has been shown 
to inhibit the growth of multiple types of human cancers. 
However, there are no reports involving the effect on nobi-
letin on human ovarian cancer. The present report shows that 
nobiletin potently decreases the viability of ovarian cancer 
cells in vitro. However, nobiletin does not affect the viability 
of normal ovarian epithelial cells at <40 µM. The antitumor 
activity of nobiletin was also observed in athymic mouse 
models and in chicken chorioallantoic membrane (CAM) 
models. The anti-neoplastic activity of nobiletin was due to its 
ability to inhibit angiogenesis. We also studied the molecular 
mechanisms by which nobiletin suppresses angiogenesis. We 
observed that nobiletin inhibits secretion of the key angiogen-
esis mediators, Akt, HIF-1α, NF-κB and vascular epithelial 
growth factor (VEGF) by ovarian cancer cells. Transient trans-
fection experiments showed that nobiletin inhibits production 
of HIF-1α by downregulation of Akt. Such decreased levels 
of HIF-1α were responsible for nobiletin-induced suppression 
of VEGF. Our data suggest that nobiletin may be a promising 
anti-angiogenic agent relevant for therapy of ovarian cancers.
Introduction
Ovarian cancer is one of the most serious malignancies for 
women in the world, ranking as the fifth leading cause of 
cancer-related deaths (1) and the death rate of ovarian cancer 
has not seen any remarkable changes for over five decades 
in the USA (2). Due to a lack of effective biomarkers for 
screening (3,4), nearly 60-70% of ovarian cancers are diag-
nosed at advanced stages (5), with a poor prognosis of ~30% 
for a 5-year survival rate (6). These facts emphasize the 
need for novel therapies to prevent and treat ovarian cancer. 
Several lines of evidence indicate that nutritional compounds 
display potent anticancer activity in many human cancers (5). 
The identification of nutritional agents that can suppress the 
growth and progression of ovarian cancer could lead to new 
treatment modalities and improved patient outcomes for this 
lethal malignancy.
Recent studies have focused on the anticancer activity of 
flavonoids isolated from plants and animals. Flavonoids are 
natural polyphenols present in a wide variety of fruits and 
vegetables (7). Some flavonoids, such as apigenin, genistein 
and catechin, have been shown to inhibit the growth of 
ovarian, breast, colon, prostate and leukemia cancer cells 
(8-17). Nobiletin (5,6,7,8,30,40-hexamethoxyflavone) is a 
polymethoxyflavonoid found in citrus fruits such as Citrus 
depressa and Citrus reticulate (18). Previous mammalian 
in vivo studies show that nobiletin can suppress inflamma-
tion-associated tumorigenesis aberrant cell proliferation and 
colon carcinogenesis (19-21). Nobiletin has been also shown 
to suppress angiogenesis in vitro in human umbilical vein 
endothelial cells. The anti-angiogenic activity of nobiletin 
has been shown in chicken chorioallantoic membranes and in 
zebrafish models (22,23). It has been revealed that nobiletin 
exhibited a cell differentiation-modulating activity (24,25) 
and inhibited the phosphorylation of MEK (26,27). Nobiletin 
is a decreases metastasis of human fibrosarcoma HT-1080 
cells and gastric cancers (27). The mitogen-activated protein 
The flavonoid nobiletin inhibits tumor growth and 
angiogenesis of ovarian cancers via the Akt pathway
JIANCHU CHEN1,2,  ALLEN Y. CHEN3,  HAIzHI HUANG1,2,  XINGqIAN YE1,   
WILLIAM D. ROLLYSON4,  HALEY E. PERRY4,  KATHLEEN C. BROWN4,   
YON ROJANASAKUL3,  GARY O. RANKIN4,  PIYALI DASGUPTA4  and  YI CHARLIE CHEN2
1College of Biosystems Engineering and Food Science, Fuli Institute of Food Science, zhejiang University, P.R. China;  
2College of Science, Technology and Mathematics, Alderson Broaddus University, Philippi, WV 26416;  
3Department of Pharmaceutical Science, West Virginia University, Morgantown, WV 26506; 4Department of Pharmacology, 
Physiology and Toxicology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA
Received February 10, 2015;  Accepted March 19, 2015
DOI: 10.3892/ijo.2015.2946
Correspondence to: Dr Yi Charlie Chen, College of Science, 
Technology and Mathematics, Alderson Broaddus University, Philippi, 
WV 26416, USA
E-mail: chenyc@ab.edu
Key words: nobiletin, ovarian cancer, angiogenesis, HIF-1α, vascular 
epithelial growth factor, Akt
CHEN et al:  NOBILETIN INHIBITS OVARIAN CANCER GROWTH2630
kinase (MAPK) signaling pathway is a key regulator of 
cell proliferation, survival and differentiation. The MAPK 
pathway is constitutively activated in ovarian cancers via gain 
of function mutations in Ras or Raf. In addition, mutations in 
PI-3 kinase pathway have been implicated in the progression 
of ovarian cancers. The hyperactivation of the MAP kinase 
pathway facilitates the neoplastic transformation of ovarian 
tumors. Selective MEK1 inhibitors have been shown to 
suppress the growth of estrogen-responsive ovarian cancers. 
Since nobiletin also functions as a MEK1 inhibitor we conjec-
tured that perhaps it could suppress the growth of human 
ovarian cancers. The growth-inhibitory activity of nobiletin 
has yet to be studied in ovarian cancer. Our report fills this 
void of knowledge and describes the anti-neoplastic activity of 
nobiletin in human ovarian cancer. In this report, we show that 
nobiletin decreases the viability of the human ovarian cancer 
cell lines OVCAR-3 and CP-70. The growth-inhibitory effects 
of nobiletin were observed at concentration as low as 5 µM. 
Nobiletin had no effect on the viability of normal ovarian 
epithelial cells at <40 µM. Therefore, it displayed a strong 
selectivity for human ovarian cancer cells over normal ovarian 
cells. Nobiletin potently decreased the growth rate of human 
ovarian tumors xenografted in athymic mouse models and 
chicken CAM models. The anticancer activity of nobiletin was 
correlated with its anti-angiogenic and anti-apoptosis activity 
in ovarian cancers. We also analyzed the signaling pathways 
underlying the anti-angiogenic activity of nobiletin. The anti-
angiogenic activity of nobiletin was correlated with decreased 
levels of Akt, HIF-1α, NF-κB and vascular epithelial growth 
factor (VEGF) in ovarian cancer cells. Taken together, our data 
suggest that nobiletin may have applications in the therapy of 
human ovarian cancer.
Materials and methods
Ethics statement. Male four-week-old athymic mice were 
obtained from Charles River Laboratories and acclimatized 
for one week. They were housed in autoclaved cages with 
ad libitum access to food and water in HEPA-filtered racks 
and closely monitored by animal facility staff. All proce-
dures involving nude mice were conducted according to the 
Animal Care and Use guidelines in a facility accredited by the 
Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) International and were approved by 
the Institutional Animal Care and Use Committee (IACUC) 
of Joan C. Edwards School of Medicine, Marshall University 
(protocol no. 560).
Reagents, antibodies and constructs. Nobiletin was prepared 
from a polymethoxyflavonoid mixture, which was provided 
by zhejiang quzhou Tiansheng Plant Extraction Co. Ltd. 
in China, containing ~60% nobiletin and tangeretin. The 
polymethoxyflavonoid mixture was dissolved in methanol-
dimethyl sulfoxide (1:1), its concentration was 50 mg/ml, then 
chromatographed with high-performance liquid chromatog-
raphy (HPLC) (Waters) eluted with methanol-H2O (70:30) in 
8 ml/min at room temperature, separated into two fractions, 
collected individually, evaporated, obtained fraction I and 
fraction II. Fraction I was identified as nobiletin (Fig. 1A) 
by HPLC-MS, UV-vis chromatography and comparing peak 
time with that of nobiletin sample from Sigma and previous 
reports (data not shown). Its purity was >98%. Monoclonal 
antibodies against HIF-1α, NF-κB (p50), PTEN, c-Myc, 
GAPDH, p-AKT, total AKT, p-mTOR and total mTOR were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). The secondary antibodies of anti-rabbit and anti-mouse 
were purchased from Thermo Scientific (Pierce, Rockford, 
IL, USA). The HIF-1α and mAkt plasmid constructs were 
obtained from Addgene (www.addgene.org) (28).
Cell culture and treatment. Human ovarian cancer cell lines, 
OVCAR-3 and A2780/CP70, were provided by Dr B. Jiang, 
Department of Microbiology, Immunology, and Cell Biology, 
West Virginia University. IOSE-364, normal ovarian surface 
epithelial cells from healthy women, but immortalized with 
SV40 T/t, were courtesy of Dr N. Auersperg at University 
of British Columbia, Canada. All cells were maintained in 
RPMI-1640 medium supplemented with 100 U/ml penicillin, 
100 µg/ml streptomycin and 10% US-qualified fetal bovine 
serum (Invitrogen, Grand Island, NY, USA) in a humidified 
incubator with 5% CO2 at 37˚C. Nobiletin was dissolved 
in dimethyl sulfoxide (DMSO) to make stock solutions of 
100 mM and equal amount of DMSO was included in controls 
for every experiment.
Cell proliferation. The effect of nobiletin on the viability of 
ovarian cancer cells (OVCAR-3 and A2780/CP70) colorimet-
rically determined with a CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay kit from Promega (Madison, WI, 
USA). The cells were seeded into 96-well plates at a density 
of 5x103/well and incubated for 24 h at 37˚C. Subsequently, 
the cells were treated with vehicle or varying concentrations 
of nobiletin for another 24 h at 37˚C. After 24 h, the medium 
was removed and cell viability was measured according to the 
manufacturer's instructions. Each sample was measured in 
triplicate. Cell viability was expressed as percentage of control 
from three independent experiments.
Apoptosis assay. The apoptotic effects of nobiletin on ovarian 
cancer cells were determined by FITC Annexin V Apoptosis 
Detection Kit I from BD Biosciences. Cells were washed 
with cold PBS twice and then were resuspended in binding 
buffer at a concentration of 1x106/ml. An aliquot of 100 µl of 
the cell solution (1x105 cells) was transferred to a 5-ml tissue 
culture tube. Subsequently, 5 µl of FITC Annexin V and 5 µl 
propidium iodide (PI) was added to the cells. The cells were 
gently vortexed and incubated for 15 min at room temperature 
in the dark. The next step involved the addition of 400 µl of 
1X binding buffer to each tube. The samples were analyzed 
by flow cytometry (Cytomic FC 500MCL) within 1 h. Three 
independent experiments were assayed. Data represent mean 
± SE from 3 independent experiments.
ELISA for VEGF. The levels of VEGF in cell culture super-
natants were analyzed by a quantikine Human VEGF 
Immunoassay kit (R&D Systems, Minneapolis, MN, USA). 
Cells (1x104/well) were seeded into 96-well plates and incu-
bated overnight. Subsequently, the cells were treated with 
nobiletin for 16 h in serum-free medium. Culture supernatants 
were collected and spun down at 10,000 g at 4˚C. The superna-
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tant was collected and stored at -70˚C. The amounts of VEGF 
were measured following the manufacturer's instructions, and 
normalized to cell numbers for each treatment. A total of three 
independent experiments, each in triplicates, were assayed, 
and the mean VEGF protein level from each triplicate was 
used for statistical analysis.
Western blot analysis. Ovarian cancer cells (106) were seeded 
in 60-mm dishes and incubated for 16 h before treated with 
nobiletin for 24 h. The cells were washed with PBS, lysed in 
100 µl mammalian protein extraction reagent including 1 l halt 
protease, 1 µl phosphatase inhibitor and 2 µl EDTA (M-PER, 
Pierce), according to the manufacturer's instructions. Total 
protein levels were assayed with a BCA Protein Assay kit 
(Pierce). Forty microgram of protein lysates was separated by 
10% SDS-PAGE and transferred into nitrocellulose membrane 
with a Mini-Protean 3 system (Bio-Rad Laboratories, Hercules, 
CA, USA). The membranes were blocked in 5% milk in PBS 
containing 0.1% Tween-20 for 1 h at room temperature. The 
membranes were incubated with the appropriate dilutions of 
the primary antibodies and secondary antibodies. The signal 
obtained in the western blot experiments was detected by the 
SuperSignal West Dura Extended Duration Substrate (Pierce 
Biotechnologies). Protein bands were quantitated with NIH 
ImageJ software, normalized by corresponding GAPDH or 
total AKT, total mTOR bands, and expressed as percentages of 
control. A total of three independent experiments were carried 
out for statistical analysis.
Transient transfection and reporter assay. Transient transfec-
tion and reporter assay were modified from our published 
report (28,29). Ovarian cancer cells were seeded in 96-well 
plate at 10,000 cells/well and incubated overnight. For 
transfection with HIF-1α/mAkt plasmids, cells were then 
transfected with 0.05 µg VEGF luciferase reporter, 0-0.25 µg 
HIF-1α/mAkt or SR-α (as vehicle) plasmids by 0.6 µl jetPRIME 
reagent (VWR) for 4 h and removed the medium. Followed 
by 16-h treatment with 0- or 40-µM nobiletin. The cells were 
harvested and analyzed for luciferase activities with ONE-Glo 
Luciferase Assay system (Promega) and detected by Lumat 
LB9507 (Berthold Technologies). Total protein levels with a 
BCA Protein Assay kit (Pierce), and the activities of VEGF 
reporter were normalized by corresponding total protein levels 
for statistical analysis. The experiments were conducted three 
times.
Chicken embryo chorioallantoic membrane (CAM) assay. 
The A2780 cells at grown to 70% confluence, were harvested, 
washed with PBS and re-suspended in serum-free medium. 
Aliquots of the cells (0.1 ml, 2x107/ml) were mixed with 0.1 ml 
of Matrigel (BD Bioscience, San Jose, CA, USA), supple-
mented with 0 or 20 µM nobiletin, pre-gelled on an autoclaved 
silicone mat for 30-40 min, and implanted onto the CAM of 
9-day-old chicken embryo. Chicken embryos were incubated 
for 4-5 days, photographed for Matrigel implant, and counted 
for branching blood vessels. Angiogenesis was evaluated by 
normalizing number of branching vessels to that of control 
CAM. A total of 10 eggs were assayed for each group.
Antitumor studies in athymic mice. Twenty-four week-old male 
nude mice were obtained from Charles River Laboratories and 
acclimatized for one week. They were housed in autoclaved 
cages with ad libitum access to food and water in HEPA-
filtered racks and closely monitored by animal facility staff. 
All procedures were conducted according to the Animal Care 
and Use guidelines in a facility accredited by the Association 
for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) International and were approved by the 
Institutional Animal Care and Use Committee (IACUC) of 
Joan C. Edwards School of Medicine, Marshall University 
(protocol no. 560).
CP70 cells were harvested and re-suspended in a 1:1 
(v/v) solution of serum-free media and Matrigel matrix 
(BD Biosciences). Two million cells in 100 µl were injected 
subcutaneously between the scapulae of each mouse (30). 
After the tumors reached 100 mm3, the mice were random-
ized and divided into two groups comprising of ten mice each. 
The treatment group (N=10) was fed AIN-76A diet with 5% 
lipid level containing 100 mg nobiletin/kg food. The control 
group (N=10) was fed AIN76A diet containing vehicle. Mice 
were weighed once per week. Their food consumption was 
monitored daily. Tumor volumes were calculated as (l x w2)/2 
(31,32).
Statistical analysis. Results are expressed as mean ± standard 
error of mean (SEM) using Microsoft Excel (Windows 8). 
Statistical assessment was carried out with the program 
system of SPSS (Version 16.0 for Windows). The results 
were analyzed using one-way analysis of variance (ANOVA) 
and post hoc test (2-sided Dunnett's test) to test both overall 
differences and specific differences between each treatment 
and control. A P-value of <0.05 was considered statistically 
significant.
Results
Effect of nobiletin on ovarian cancer cell viability. The 
treatment of OVCAR-3 and CP70 ovarian cancer cells with 
nobiletin caused a concentration-dependent decrease in cell 
viability over 24 h. Beginning at a concentration of 5 µM 
nobiletin, OVCAR-3 cell viability consistently decreased 
from 95±1 to 28±4% at a concentration of 160 µM nobiletin 
(P<0.01) (Fig. 2A). Similarly, CP70 cell viability was also 
suppressed with different concentration. At a concentration of 
5 µM nobiletin cell viability was 96±1% (P<0.05), that was 
gradually inhibited to 26±3% by a 160-µM nobiletin treatment 
Figure 1. Structure of nobiletin.
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(P<0.01) (Fig. 2B). We also examined the growth inhibi-
tory activity of nobiletin on IOSE-364 normal ovarian cells 
(Fig. 2C). We observed that nobiletin had a lower growth-
inhibitory activity in IOSE-364 cells than in A2780 ovarian 
cancer cells. Therefore, our data suggest that nobiletin is 
somewhat more selective towards ovarian cancer cells than 
normal cells.
Effect of nobiletin on ovarian cancer cell apoptosis. We 
ascertained that the growth inhibitory effects of nobeletin 
were due to cellular apoptosis. Annexin FITC assays 
revealed that nobiletin induced apoptosis in CP70 ovarian 
cancer cells in a concentration-dependent manner (Fig. 2D). 
CP70 cell apoptosis was 13±1% when it was not treated with 
nobiletin, which was significant increased at a concentration 
of 10 µM nobiletin (26±2%). CP70 cell apoptosis was gradu-
ally increased to 88±2% by a 160-µM nobiletin treatment 
(P<0.01).
Effect of nobiletin on angiogenesis and growth of the tumor. 
To assess whether nobiletin inhibits the growth of human 
ovarian cancers in vivo, we used the CAM and athymic 
mouse models to study the effect of nobiletin on the growth 
rate of human ovarian cancer cells in vivo. The administra-
tion of 20 µM nobiletin significantly attenuated (P<0.01) 
the growth of OVCAR human ovarian tumors implanted 
on CAM (Fig. 3A and B). We counted the number of blood 
vessels to assess whether nobiletin was suppressing the 
growth of ovarian tumors by inhibition of angiogenesis. The 
chicken CAM experiment was repeated using A2780 cells 
and similar results were obtained. We observed that the 
treatment of OVCAR and A2780 cells with 20 µM nobiletin 
was able to inhibit angiogenesis. The implanted cancer 
cells grow to a tumor weight of 58±5 mg, with 29±4 blood 
vessels counted. Inclusion of 20 µM nobiletin in this implant, 
however, reduced tumor growth down to 34±3 mg (P<0.01) 
and inhibited blood vessel development to 19±2 (P<0.05). We 
speculated that the effect of nobiletin on the promotion of 
cancer cell apoptosis and inhibition of angiogesis lead to the 
growth attenuation of tumors implanted on CAM. A typical 
image (Fig. 3C) is shown to contrast the tumors with or 
without nobiletin in terms of both tumor size and angiogen-
esis. The great effect of nobiletin on inhibiting tumor growth 
was conformed in vivo using an athymic mouse model, where 
they exhibited smaller tumor size (Fig. 3D). The tumors 
implanted on mice grow to a volume of 2450 mm3 at the 15th 
day. However, the treatment of nobiletin (100 mg/kg food) 
inhibited tumor growth to 300 mm3.
Effect of nobiletin on VEGF expression. Our results showed 
that nobiletin significantly inhibited the expression of vascular 
endothelial grow factor (VEGF) in ovarian cancer cells, 
Figure 2. Nobeletin decreased the viability and induced apoptosis of human ovarian cancer cells in a concentration-dependent manner. (A) Cell viability 
assays showed that the treatment of OVCAR-3 cells with varying concentrations of nobiletin caused a decrease in cell viability. (B) The cell viability assay 
was repeated in A2780/CP70 cells. (C) Cell viability results were obtained in IOSE-364 cells. (D) Apoptosis assay showed that nobiletin induced apoptosis of 
A2780/CP70 ovarian cancer cells. Data represent mean ± SE from 3 independent experiment. *P<0.05 as compared to control. **P<0.01 as compared to control.
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and this inhibition effect was enhanced with the increase of 
nobiletin concentration (Fig. 4). In both OVCAR-3 and A2780/
CP-70 cells, the inhibitory effect of nobiletin on VEGF secre-
tion reached a significant level when its concentration was 
>20 µM. The levels of secreted VEGF protein in OVCAR-3 
cell culture supernates were downregulated to 77±2% at a 
concentration of 10 µM nobiletin (P<0.01) and to 28±1% at a 
concentration of 160 µM nobiletin (P<0.01) (Fig. 4A). Similarly 
the levels of secreted VEGF protein in CP70 cells ranged from 
66±2% (20 µM) to 16±2% (160 µM) with respect to different 
nobiletin concentration (Fig. 4B).
Signaling pathways underline the growth inhibiting activity 
of nobiletin. HIF-1α is one of the key factors for the regula-
Figure 3. Nobiletin inhibits tumor growth and angiogenesis in CAM and athymic mouse models. Chicken chorioallantoic membrane (CAM) assay showing 
tumor without nobiletin treatment (A), treated with 20 µM nobiletin (B). CAM assays showed that 20 µM nobiletin suppressed the growth of blood vessels and 
A2780/CP70 tumors xenografted on chicken CAM relative to vehicle treated tumors (C). After 5 days of treatment, the tumors were excised, and the blood 
vessels were counted by phase contrast microscopy. Angiogenesis was evaluated by normalizing number of branching vessels to that of control CAM. The data 
are presented as mean ± SEM (n=10 eggs/group) (C). Nobiletin treatment also significantly inhibited tumor growth in the athymic mice (D).
Figure 4. Nobiletin induces a concentration-dependent decrease of VEGF production from human ovarian cancer cells. The human ovarian cancer cell line 
OVCAR-3 (A), and A2780/CP70 (B) were treated with varying concentrations of nobiletin for 16 h. Subsequently, the VEGF levels in the supernatant was 
measured by ELISA. A total of three independent experiments, each in triplicates, were assayed, and the mean VEGF protein level from each duplicate was 
used for statistical analysis. *P<0.05 as compared to control. **P<0.01 as compared to control.
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tion of VEGF expression. As shown in Fig. 5A, nobiletin had a 
certain impact on HIF-1α expression of ovarian cancer cells. 
For OVCAR-3, 20-µM nobiletin treatment led to inhibition 
of HIF-1α protein to 78±6% by 24 h of treatment. Higher 
concentrations of nobiletin resulted in greater inhibition, 
with the levels of HIF1-α protein down to 57±3% by 40-µM 
nobiletin treatment (P<0.01) and 23±3% by 80-µM nobiletin 
treatment (P<0.01). However, for CP70, HIF-1α expression 
was slightly enhanced (118±2%) when the concentration 
of nobiletin was <20 µM and was significantly inhibited 
(47±2%) when its concentration was 80 µM (P<0.01). It seems 
CP70 cells were more resistant to the effect of nobiletin than 
OVCAR-3 cells on HIF-1α expression.
Nobiletin inhibited phosphorylation of AKT, which is 
known to be the major signal for cell survival and prolif-
eration (33). As shown in Fig. 5B, nobiletin decreased AKT 
phosphorylation for both OVCAR-3 and CP70 ovarian cancer 
cells. P-AKT level was downregulated from 70±2% by 20-µM 
nobiletin treatment to 29±4% by 80-µM nobiletin treatment in 
OVCAR-3 cells. The phosphorylation of AKT was also inhib-
ited from 69±1% by the 20-µM nobiletin treatment to 49±1% 
by 40-µM nobiletin treatment in CP70 cells. However, the 
effect of nobiletin on the inhibition of AKT phosphorylation in 
C70 cells was decreased when treated with 160-µM nobiletin. 
Again, it seems CP70 cells were more resistant to the effect of 
nobiletin than OVCAR-3 cells on AKT phosphorylation.
Figure 5. Nobiletin regulates several intracellular signaling pathways in human OVCAR-3 and CP-70 ovarian cells. (A) Nobiletin decreases the levels of 
HIF-1α in OVCAR-3 and CP-70 human ovarian cells. Protein bands were quantitated, normalized by corresponding GAPDH bands, and expressed as 
percentages of control (bar graph below the panel). (B) Nobiletin lowers the phosphorylation of Akt (Ser4) in OVCAR-3 and CP-70 cells. The levels of total Akt 
are not affected by nobiletin treatment. The bar graph below the panel represents densitometric analysis of the immunoblotting data. (C) Nobiletin decreases 
NF-κB expression in both ovarian cancer cell lines. (D) Nobiletin had no effect on expression of c-Myc, PTEN, mTOR proteins. Nobiletin had no effect on 
the phosphorylation of mTOR protein in either ovarian cancer cell line. A total of three independent experiments were carried out for statistical analysis. Data 
represent mean ± SE from 3 independent experiment. *P<0.05 as compared to control. **P<0.01 as compared to control.
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NF-κB is a common transcription factor that is related to 
many signal transduction pathways of cancer cell proliferation 
and angiogenesis (34,35). The effect of nobiletin on NF-κB 
expression is shown in Fig. 5C. Results showed that nobiletin 
had an impact on NF-κB (p50) expression. The level of NF-κB 
(p50) decreased with the increase of nobiletin concentration 
in OVCAR-3 and CP-70 cells. For OVCAR-3, the inhibitory 
effect reached a significant level (87±1%) when the concentra-
tion of nobiletin was 20 µM (P<0.01). In CP70, NF-κB (p50) 
level reduced with the increase of nobiletin concentration, and 
it reached a significant level when the nobiletin concentration 
was 20 (88±1%) and 80 µM (57±6%) (P<0.05).
c-Myc is a transcription factor that plays a role in cell cycle 
progression, apoptosis and cellular transformation. Unlike 
kaempferol, which inhibited c-Myc protein expression (35), our 
results indicated that nobiletin did not inhibit c-Myc expres-
sion in ovarian cancer cells (Fig. 5D). Its mechanism needs to 
be further investigated. PTEN acts as a tumor suppressor gene 
which is involved in the regulation of the cell cycle, preventing 
cells from growing and dividing too rapidly (36). The protein 
of mTOR is a serine/threonine protein kinase that regulates 
cell growth, cell proliferation, cell motility, cell survival, 
protein synthesis, and transcription (37). Results also showed 
that nobiletin had no significant effect on PTEN and p-mTOR 
expression in ovarian cancer OVCAR-3 and CP-70 (Fig. 5D).
Nobiletin inhibits VEGF by regulating HIF-1α expression and 
Akt signaling. To see that HIF-1 is not only regulated by nobi-
letin treatment, but also plays a role in the nobiletin inhibition 
on VEGF expression, ovarian cancer cells were transfected 
with the VEGF-promoter reporter together with HIF-1 plas-
mids. While nobiletin treatment significantly inhibited VEGF 
transcriptional activation, this inhibition was concentration-
dependent and significantly reversed by forced expression of 
HIF-1α protein (Fig. 6A).
The role played by Akt signaling in the nobiletin regula-
tion of VEGF expression was investigated in both ovarian 
cell lines. It was found that the phosphorylation of Akt was 
significantly inhibited by 2-h nobiletin treatment (Fig. 6B). 
After transfecting with VEGF-promoter reporter and mAkt 
plasmids, VEGF transcriptional activation was significantly 
reduced by nobiletin treatment in both ovarian cancer cell 
types, and this effect was significantly reversed by forced 
expression of Akt protein (Fig. 6B).
Discussion
Angiogenesis is a necessary condition for sustained tumor 
growth. Tumor cells take in nutrition and oxygen through the 
generated blood vessels, which produce substances needed for 
growth (38). Angiogenesis plays a central role in the devel-
opment and progression of ovarian cancer (39). Histological 
studies demonstrated that ovarian tumors are richly vascu-
Figure 6. Forcing expression of HIF-1α protein (A) and Akt protein (B) 
reversed the effect of nobiletin on VEGF transcriptional activation. 
OVCAR-3 and A2780/CP70 cancer cells were seeded in a 96-well plate at 
10,000 cells/well and incubated overnight. The cells were then transfected 
with 0.05 µg VEGF (HIF-1α) luciferase reporter, 0-0.25 µg HIF-1α (AKT) 
or SR-α plasmids by 0.6 µl jetPRIME reagent for 4 h, followed by 16-h treat-
ment with 0 or 40 µM nobiletin. The cells were harvested and analyzed for 
luciferase and total protein levels, and the levels of VEGF (HIF-1α) reporter 
were normalized by corresponding total protein levels. Data represent mean 
± SE from 3 independent experiment. *P<0.05 as compared to control. 
**P<0.01 as compared to control.
Figure 7. Proposed pathway for the nobiletin effect on tumor growth and 
angiogenesis. 
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larized. A correlation between microvascular count and 
biological aggressiveness was also found (40,41). Vascular 
endothelial growth factor (VEGF), as a key regulator of 
angiogenesis in ovarian cancer, is involved in various steps 
of ovarian carcinogenesis (42,43). VEGF plays a central role 
in tumor vasculature development and maintenance. VEGF 
expression promotes angiogenesis, thereby stimulating tumor 
growth and metastasis. Hypoxia-inducible factor 1α (HIF-1α) 
is a heterodimeric basic helix-loop-helix protein that directly 
activates transcription of VEGF gene by binding to a HRE 
(44). Previous studies showed that nobiletin inhibited angio-
genesis in human umbilical vein endothelial cells (HUVECs) 
and zebrafish models (22,23,45). Similarly, the results showed 
that nobiletin effectively inhibited angiogenesis in ovarian 
cancer cells planted on chicken embryos models, indicating 
its potential to inhibit tumor growth in vivo.
While VEGF expression is an important factor in tumor 
growth and metastasis, HIF-1α is one of the key factors for 
VEGF expression. Previous studies (46,47) showed that the 
anticancer flavonoid compound kaempferol inhibited angio-
genesis in ovarian cancer cells by downregulating HIF-1α 
expression. This is consistent with our study, indicating that 
the nobiletin inhibitory effects on angiogenesis can be traced 
back to suppression of HIF-1α expression. However, contradic-
tory results were found in zebrafish models which showed that 
nobiletin increased mRNA levels of VEGF (22). This could be 
because nobiletin induced anti-angiogenesis through different 
mechanism in the two kinds of cells. PI3 kinase/Akt pathways 
could attenuate ovarian carcinoma through mediating angio-
genesis and vascular permeability (48). In addition, taking 
into consideration previous studies that HIF-1α is related to 
the PI3 kinase/Akt signaling pathways (30-32), we tested if 
nobiletin inhibited expression of VEGF through PI3K/AKT 
pathways. Our results revealed that nobiletin significantly 
inhibited the phosphorylation of Akt. The inhibitory effect of 
nobiletin on Akt phosphorylation was more pronounced than 
on HIF-1α expression shown above. Previous studies showed 
that nobiletin suppressed PI3K/Akt pathways in human 
HepG2 (49). It was similar to our findings that nobiletin 
inhibited angiogenesis mainly through Akt pathways which 
results in the downregulation of VEGF expression (Fig. 6B). 
The mechanism by which nobiletin inhibits the PI3K/Akt 
signaling pathway is not fully understood. However, it has 
been shown that nobiletin suppressed invasion and migration 
of human gastric adenocarcinoma AGS cells through FAK/
PI3K/Akt pathways (50).
Some researchers found that Akt pathways regulates the 
expression, activation and translocation of NF-κB (51-53). 
Suppression of NF-κB in tumor samples also inhibits prolif-
eration, causes apoptosis, indicating the crucial role of NF-κB 
in cell proliferation and survival. We consider that it plays an 
important role on the nobiletin-induced apoptosis in A2780/
CP70 cells. It was also found that HIF-1α promoter is respon-
sive to selective NF-κB subunits, indicating that NF-κB is a 
direct modulator of HIF-1α expression (54). NF-κB, which is 
related to many signal transduction pathways of cancer cells 
(34), has been identified in tumors of epithelial origin such as 
breast, colon, lung and ovarian cancers (55). Recent research 
suggested the importance of NF-κB in the propagation of 
ovarian cancer cell lines (56). It was also found that NF-κB 
had a relationship with angiogenesis; that is, NF-κB regulates 
c-Myc expression. Overexpression of NF-κB removed the 
kaempferol inhibitory effect on c-Myc expression (35). Our 
results showed that the effect of nobiletin on NF-κB in ovarian 
cancer cells varies with cancer cells. Similar to the results found 
in AKT phosphorylation, NF-κB levels in the OVCAR-3 cells 
were more sensitive than those in the CP70 line. Nevertheless, 
nobiletin treatment significantly reduced NF-κB expression 
in both cell lines in a concentration-dependent manner. As 
previous study showed NF-κB have been linked to regulation 
of VEGF production (57), we conclude nobiletin antagonizes 
VEGF expression through NF-κB (Fig. 7).
The proposed mechanism by which nobiletin hampers 
angiogenesis involves lowering concentrations of VEGF regu-
lators, namely HIF-1α and NF-κB (Fig. 7). We found nobiletin 
to have little effect on c-Myc, PTEN, and p-mTOR expression, 
which indicates that nobiletin does not inhibit expression of 
VEGF through PTEN/mTOR pathways, neither is c-Myc the 
key protein that is affected by nobiletin treatment in ovarian 
cells. Noteworthy, both HIF-1α and Akt were demonstrated to 
play direct roles in VEGF secretion. Overexpression of either 
protein in the presence of nobiletin neutralized its VEGF 
diminishing effects. Since Akt phosphorylation is intimately 
linked to HIF-1α activation, it is likely nobiletin exerts its 
cancer fighting properties through blocking Akt phosphory-
lation. Impeding Akt activity likewise reduces HIF-1α and 
NF-κB levels, subsequently dropping VEGF production and 
obstructing angiogenesis. Considering all the evidence, we 
believe this is the central pathway through which nobiletin 
mediates its tumor limiting effects.
Importantly, our in vitro research conducted agrees with 
both of our in vivo models. In our CAM model, nobiletin treat-
ment significantly reduced not only the tumor size but also the 
number of blood vessels, confirming its potency in countering 
angiogenesis. Furthermore, nobiletin also suppressed tumor 
growth rates of CP-70 human ovarian cancer cells in the nude 
mouse model. The administration of nobiletin did not cause 
any discomfort in mice. The weights of mice, their food intake, 
water intake were unaffected by the administration of nobi-
letin (data not shown).
The challenge of conventional chemotherapy in ovarian 
cancer is that chemotherapeutic drugs are also toxic to 
normal ovarian epithelial cells. We find that nobiletin potently 
inhibits the viability of human ovarian cancer cells, and has 
minimal effects of the viability of normal ovarian cells. The 
selective inhibitory effect might be at least partly attributed 
to the apoptosis and anti-angiogenesis induced by nobiletin. 
Overexpression and activation of Akt, which results in the 
survival of cancer cells that normally undergo apoptosis (58), 
occurs in different kinds of cancers, such as gastric, lung, 
panacreatic and ovarian cancer (59). Nobiletin inhibits overian 
cancer cells selectively, possibly due to its effect on the phos-
phorylation of Akt.
Platinum drugs have been most frequently applied for 
the treatment of cancers including ovarian cancer. However, 
acquired resistance to conventional platinum based chemo-
therapy has become a major impediment in cancer treatment. 
Novel therapies that can reverse drug resistance or kill drug 
resistant ovarian cancer cells directly are highly desired. 
Flavonoid compounds like tangeretin (60) and kaempferol 
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(61) have been shown to sensitize ovarian cancer cells to 
the apoptotic effects of cisplatin. Since nobiletin selectively 
inhibits ovarian cancer cells, it is expected that nobiletin may 
be useful both as a single agent as well as in combination 
therapies in the treatment of ovarian cancers.
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